Rational use of mucoactive medications to treat pediatric airway disease

Paediatr Respir Rev. 2020 Nov:36:8-14. doi: 10.1016/j.prrv.2020.06.007. Epub 2020 Jun 16.

Abstract

Many airway diseases in children, notably bronchiolitis, cystic fibrosis (CF), non-CF bronchiectasis including primary ciliary dyskinesia, pneumonia, and severe asthma are associated with retention of airway secretions. Medications to improve secretions clearance, the mucoactive medications, are employed to treat these diseases with varying degrees of success. This manuscript reviews evidence for the use of these medications and future directions of study.

Keywords: Airway diseases; Cystic fibrosis; Dornase; Mucoactive medications; Mucolytics; Sputum.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Adrenal Cortex Hormones / therapeutic use
  • Asthma / drug therapy*
  • Bronchiectasis / drug therapy*
  • Bronchiolitis, Viral / drug therapy*
  • Child
  • Child, Preschool
  • Cholinergic Antagonists / therapeutic use
  • Ciliary Motility Disorders / drug therapy*
  • Cystic Fibrosis / drug therapy*
  • Deoxyribonuclease I / therapeutic use
  • Diuretics, Osmotic / therapeutic use
  • Epithelial Sodium Channel Blockers / therapeutic use
  • Expectorants / therapeutic use*
  • Humans
  • Infant
  • Macrolides / therapeutic use
  • Mannitol
  • Recombinant Proteins / therapeutic use
  • Respiratory System Agents / therapeutic use*
  • Saline Solution, Hypertonic
  • Severity of Illness Index

Substances

  • Adrenal Cortex Hormones
  • Cholinergic Antagonists
  • Diuretics, Osmotic
  • Epithelial Sodium Channel Blockers
  • Expectorants
  • Macrolides
  • Recombinant Proteins
  • Respiratory System Agents
  • Saline Solution, Hypertonic
  • Mannitol
  • Deoxyribonuclease I
  • dornase alfa